157 related articles for article (PubMed ID: 34525887)
1. Analysis of patients' access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece.
Seitaridou Y; Tsekov I; Kamusheva M; Dimitrova M; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):241-246. PubMed ID: 34525887
[TBL] [Abstract][Full Text] [Related]
2. Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries.
Kamusheva M; Manova M; Savova AT; Petrova GI; Mitov K; Harsányi A; Kaló Z; Márky K; Kawalec P; Angelovska B; Lakić D; Tesar T; Draganic P; Geitona M; Hatzikou M; Paveliu MS; Männik A
Front Pharmacol; 2018; 9():795. PubMed ID: 30079023
[No Abstract] [Full Text] [Related]
3. An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries.
Kamusheva M; Vassileva M; Savova A; Manova M; Petrova G
Front Public Health; 2018; 6():61. PubMed ID: 29556491
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapeutic Patterns and Patients' Access to Pharmacotherapy for Some Rare Diseases in Bulgaria - A Pilot Comparative Study.
Kamusheva M; Dimitrova M; Tachkov K; Petrova G; Mitkova Z
Front Pharmacol; 2021; 12():695181. PubMed ID: 34349654
[TBL] [Abstract][Full Text] [Related]
5. Affordability of medicines in the European Union.
Zaprutko T; Kopciuch D; Kus K; Merks P; Nowicka M; Augustyniak I; Nowakowska E
PLoS One; 2017; 12(2):e0172753. PubMed ID: 28241019
[TBL] [Abstract][Full Text] [Related]
6. Availability and reimbursement of biological products for severe asthma in Bulgaria.
Milushewa P; Doneva M; Petrova G
SAGE Open Med; 2020; 8():2050312120951067. PubMed ID: 32922787
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria.
Karanyotova S; Topova B; Petrova E; Doychev P; Kapitanska E; Petrova G; Mitkova Z; Dimitrova M
Front Public Health; 2023; 11():1073733. PubMed ID: 36935674
[TBL] [Abstract][Full Text] [Related]
8. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
[No Abstract] [Full Text] [Related]
9. Pharmaceutical pricing and reimbursement reforms in Greece.
Yfantopoulos J
Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
[TBL] [Abstract][Full Text] [Related]
10. Time From Marketing Authorization to Reimbursement of Medicines in Greece After the Introduction of the Health Technology Assessment Process From July 2018 to April 2022.
Beletsi A; Stefanou G; Kourlaba G
Value Health Reg Issues; 2023 Jul; 36():58-65. PubMed ID: 37030032
[TBL] [Abstract][Full Text] [Related]
11. Drug Policy in Bulgaria.
Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
[TBL] [Abstract][Full Text] [Related]
12. Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape.
Kostadinov K; Marinova Y; Dimitrov K; Hristova-Atanasova E; Iskrov G; Stefanov R
Healthcare (Basel); 2024 Feb; 12(4):. PubMed ID: 38391833
[TBL] [Abstract][Full Text] [Related]
13. Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria.
Mitkova Z; Dimitrova M; Doneva M; Tachkov K; Kamusheva M; Marinov L; Gerasimov N; Tcharaktchiev D; Petrova G
Front Public Health; 2022; 10():1011928. PubMed ID: 36438231
[TBL] [Abstract][Full Text] [Related]
14. Access to Care for Multiple Sclerosis in Times of Economic Crisis in Greece--the HOPE II Study.
Souliotis K; Alexopoulou E; Papageorgiou M; Politi A; Litsa P; Contiades X
Int J Health Policy Manag; 2015 Sep; 5(2):83-9. PubMed ID: 26927393
[TBL] [Abstract][Full Text] [Related]
15. PRICING, REIMBURSEMENT, AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINAL PRODUCTS IN BULGARIA.
Benisheva-Dimitrova T; Sidjimova D; Cherneva D; Kralimarkov N
Int J Technol Assess Health Care; 2017 Jan; 33(3):365-370. PubMed ID: 28831942
[TBL] [Abstract][Full Text] [Related]
16. Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.
Kostadinov K; Popova-Sotirova I; Marinova Y; Musurlieva N; Iskrov G; Stefanov R
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672571
[TBL] [Abstract][Full Text] [Related]
17. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
Ferrario A
Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
[TBL] [Abstract][Full Text] [Related]
18. Organisation and financing of the health care systems of Bulgaria and Greece -- what are the parallels?
Exadaktylos NM
BMC Health Serv Res; 2005 May; 5():41. PubMed ID: 15921530
[TBL] [Abstract][Full Text] [Related]
19. Does EU and US paediatric legislation improve the authorization availability of medicines for children in other countries?
Volodina A; Shah-Rohlfs R; Jahn A
Br J Clin Pharmacol; 2023 Mar; 89(3):1056-1066. PubMed ID: 36189466
[TBL] [Abstract][Full Text] [Related]
20. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
Iskrov G; Miteva-Katrandzhieva T; Stefanov R
Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
